(Q33431391)

26 July 2017

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study (English)

1 reference

26 July 2017

1 reference

6

Xavier Leleu

0 references

Catherine Thieblemont

19

Catherine Thieblemont

1 reference

26 July 2017

13

François Lokiec

0 references

Keyvan Rezai

Keyvan Rezai

10

0 references

Emanuele Zucca

Emanuele Zucca

18

0 references

David Cunningham

David Cunningham

17

0 references

Thierry Facon

15

Thierry Facon

1 reference

26 July 2017

16

Antonio Palumbo

1 reference

26 July 2017

Sandy Amorim

1

1 reference

26 July 2017

Anastasios Stathis

2

1 reference

26 July 2017

Mary Gleeson

3

1 reference

26 July 2017

Sunil Iyengar

4

1 reference

26 July 2017

Valeria Magarotto

5

1 reference

26 July 2017

Franck Morschhauser

7

1 reference

26 July 2017

Lionel Karlin

8

1 reference

26 July 2017

Florence Broussais

9

1 reference

26 July 2017

Patrice Herait

11

1 reference

26 July 2017

Carmen Kahatt

12

1 reference

26 July 2017

François Lokiec

13

1 reference

26 July 2017

Gilles Salles

14

1 reference

26 July 2017

18 March 2016

1 reference

26 July 2017

The Lancet. Haematology.

1 reference

26 July 2017

3

1 reference

26 July 2017

e196-204

1 reference

26 July 2017

4

1 reference

Targeting bromodomains: epigenetic readers of lysine acetylation

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Selective inhibition of tumor oncogenes by disruption of super-enhancers

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Selective inhibition of BET bromodomains

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Revised response criteria for malignant lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

Tumor microenvironment: becoming sick of Myc.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

MYC on the path to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900021-1

7 January 2021

10.1016/S2352-3026(16)00021-1

Identifiers

DOI

1 reference

26 July 2017

1 reference